Evidence map›Paper›PMID 42697858›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2026

Distinct Prognostic Roles of Grade Group and Intraductal Carcinoma of the Prostate in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Junichi Ikeda, Hisanori Taniguchi, Monta Inoue, Yuki Masuo, Takahiro Nakamoto, Makoto Taguchi, Seiji Shimada, Takao Mishima, Masaaki Yanishi, Katsunori Uchida and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Junichi IkedaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID https://orcid.org/0000-0002-0797-8525
Hisanori TaniguchiDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID https://orcid.org/0000-0002-7404-0369
Monta InoueDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Yuki MasuoDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID https://orcid.org/0000-0001-8876-8839
Takahiro NakamotoDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID https://orcid.org/0009-0006-7540-1812
Makoto TaguchiDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Seiji ShimadaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Takao MishimaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Masaaki YanishiDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Katsunori UchidaDepartment of Pathology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID https://orcid.org/0009-0000-9661-5605
Hidefumi KinoshitaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe study aimed to evaluate the impact of grade group (GG) and intraductal carcinoma of the prostate (IDC-P), as established prognostic factors, on clinical endpoints in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen receptor signaling inhibitors (ARSIs).

methodsWe retrospectively analyzed 147 patients with mHSPC treated with androgen deprivation therapy and ARSIs (abiraterone acetate, enzalutamide, or apalutamide). Associations between clinicopathological factors, including GG 5 and IDC-P, and prostate-specific antigen progression-free survival (PSA-PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated by Kaplan-Meier analysis and Cox proportional hazards models.

resultsGG 5 was identified in 66% of patients, and IDC-P was present in 51% of patients. GG 5 was an independent predictor of PSA-PFS, whereas IDC-P was not. In contrast, IDC-P was independently associated with poorer CSS, while GG was not. Neither IDC-P nor GG was significantly associated with OS. The combined evaluation of GG 5 and IDC-P showed the best prognostic predictive ability for PSA-PFS, CSS, and OS.

conclusionsIn patients with ARSI-treated mHSPC, both GG 5 and IDC-P are important prognostic factors, although they play distinct roles in predicting clinical outcomes.

Indexed as

Androgen Receptor AntagonistsProstatic NeoplasmsAbiraterone AcetateAgedAged, 80 and overBenzamidesHumansMaleMiddle AgedNeoplasm GradingNitrilesPhenylthiohydantoinPrognosisProgression-Free SurvivalProstateProstate-Specific AntigenAbiraterone AcetateAndrogen Receptor AntagonistsapalutamideBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific AntigenReceptors, AndrogenThiohydantoinsandrogen receptor pathway inhibitorandrogen receptor signaling inhibitorgrade groupintraductal carcinoma of the prostatemetastatic hormone‐sensitive prostate cancer

Identifiers

PMID42697858
PMCPMC13545015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.